Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Codiak BioSciences, Inc. (CDAK)
|
Add to portfolio |
|
|
|
| Price: |
$12.02
| | Metrics |
| OS: |
22.7
|
M
| |
-45
|
% ROE
|
| Market cap: |
$272
|
M
| |
-25
|
% ROIC
|
|
Net cash:
|
$16.2
|
M
| |
$0.71
|
per share
|
|
EV:
|
$256
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($15.4)
|
M
| |
|
|
|
EBIT
|
($20.1)
|
M
| |
|
|
| EPS |
($0.87)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 22.9 | 2.9 | 0.4 | 0.0 | 21.3 |
| Revenue growth | 686.8% | 651.3% | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 42.6 |
| Gross profit | 22.9 | 2.9 | 0.4 | 0.0 | -21.3 |
| Gross margin | 100.0% | 100.0% | 100.0% | | -100.0% |
| Research and development | 64.9 | 74.0 | 59.5 | 28.5 | |
| General and administrative | 27.6 | 19.9 | 21.0 | 9.9 | 6.2 |
| EBIT | -36.3 | -90.9 | -80.2 | -38.4 | -27.5 |
| EBIT margin | -158.1% | -3119.0% | -20657.7% | | -129.0% |
| Pre-tax income | -37.2 | -91.7 | -78.0 | -44.5 | -27.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -37.2 | -102.5 | -91.7 | -58.2 | 0.0 |
| Net margin | -162.0% | -3516.2% | -23624.0% | | -0.2% |
| |
| Diluted EPS | ($1.70) | ($16.18) | ($30.66) | ($23.07) | ($1.88) |
| Shares outstanding (diluted) | 21.8 | 6.3 | 3.0 | 2.5 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|